Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Clinical trial NCT03425643 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03425643
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-24
- Primary completion
- 2023-07-10
- Enrollment
- 797
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.